Analyst consensus rating
Kazia Therapeutics Analyst Rating: Strong Buy
Direct answer
Kazia Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.30.
Forecast evidence checked November 16, 2026.
Get free Kazia Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.62
- Average price target
- $28.30
- High price target
- $38.47
- Low price target
- $16.95
- Low target gap
- +156%
- Target upside
- +327.4%
- High target gap
- +481.1%
- Target range width
- 325.1%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- November 16, 2026
- Valid through
- November 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kazia Therapeutics?
Kazia Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $28.30.
How far are Kazia Therapeutics's low and high targets from the recorded price?
The low target implies +156%, while the high target implies +481.1%.
How many analysts are included in Kazia Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Kazia Therapeutics's target upside or downside calculated?
The average target of $28.30 is divided by the recorded price of $6.62, then one is subtracted to produce +327.4%. This does not guarantee a future return.
When was Kazia Therapeutics's analyst forecast verified?
The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.